度普利尤单抗治疗成人特应性皮炎的真实世界有效性和耐受性：一项针对首批100例接受治疗患者的单中心、前瞻性1年观察性队列研究 - Suppr

Suppr

超能文献

Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated.

作者信息

Sears A V, Woolf R T, Gribaleva E, Abdelrahman W, Robbie S, Menon B, Kirkham B, Smith C H, Pink A E

机构信息

St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

出版信息

Br J Dermatol. 2021 Apr;184(4):755-757. doi: 10.1111/bjd.19631. Epub 2021 Feb 28.

DOI:10.1111/bjd.19631

PMID:33107978

Abstract

摘要

相似文献

Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated.

Br J Dermatol. 2021 Apr;184(4):755-757. doi: 10.1111/bjd.19631. Epub 2021 Feb 28.

Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.

J Am Acad Dermatol. 2021 Jan;84(1):139-147. doi: 10.1016/j.jaad.2020.08.051. Epub 2020 Aug 18.

Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.

BMC Dermatol. 2020 Sep 22;20(1):8. doi: 10.1186/s12895-020-00103-0.

Real-world persistence with dupilumab among adults with atopic dermatitis.

Ann Allergy Asthma Immunol. 2021 Jan;126(1):40-45. doi: 10.1016/j.anai.2020.07.026. Epub 2020 Jul 31.

[Ocular symptoms associated with dupilumab in atopic dermatitis].

Ned Tijdschr Geneeskd. 2019 Mar 21;163:D3227.

Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.

Cornea. 2020 Jun;39(6):784-786. doi: 10.1097/ICO.0000000000002262.

Rosacea associated with dupilumab therapy.

J Dermatolog Treat. 2021 Feb;32(1):114-116. doi: 10.1080/09546634.2019.1624683. Epub 2019 Jun 9.

Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia Successfully Treated With Dupilumab.

J Investig Allergol Clin Immunol. 2021 Jun 22;31(3):261-263. doi: 10.18176/jiaci.0614. Epub 2020 Jul 30.

Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case report.

J Dtsch Dermatol Ges. 2020 Jul;18(7):740-742. doi: 10.1111/ddg.14074. Epub 2020 Mar 25.

Onset of Schamberg Disease and Resolution of Alopecia Areata During Treatment of Atopic Dermatitis With Dupilumab.

J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):65-66. doi: 10.18176/jiaci.0541. Epub 2020 Jun 3.

引用本文的文献

Use of dupilumab for recalcitrant bullous pemphigoid: A case report.

SAGE Open Med Case Rep. 2024 Aug 22;12:2050313X241274855. doi: 10.1177/2050313X241274855. eCollection 2024.

Treatment patterns and factors associated with discontinuation of monoclonal antibodies.

SAGE Open Med. 2024 Aug 19;12:20503121241271817. doi: 10.1177/20503121241271817. eCollection 2024.

Immune-Targeted Therapies for Depression: Current Evidence for Antidepressant Effects of Monoclonal Antibodies.

J Clin Psychiatry. 2024 Jun 24;85(3):23nr15243. doi: 10.4088/JCP.23nr15243.

A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities.

JAAD Int. 2024 Jan 17;15:5-11. doi: 10.1016/j.jdin.2024.01.002. eCollection 2024 Jun.

Dupilumab-Associated Arthritis: A Dermatology-Rheumatology Perspective.

Am J Clin Dermatol. 2023 Nov;24(6):859-864. doi: 10.1007/s40257-023-00804-5. Epub 2023 Jun 22.

High loading-dose of dupilumab resulted in rapid disease control in pediatric patients with atopic dermatitis.

Front Immunol. 2023 Apr 20;14:1160710. doi: 10.3389/fimmu.2023.1160710. eCollection 2023.

Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management.

Cornea. 2023 Apr 1;42(4):507-519. doi: 10.1097/ICO.0000000000003162. Epub 2022 Dec 15.

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials.

Dermatol Ther (Heidelb). 2022 Dec;12(12):2731-2746. doi: 10.1007/s13555-022-00822-x. Epub 2022 Oct 21.

Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study.

Dermatol Ther (Heidelb). 2022 Sep;12(9):2145-2160. doi: 10.1007/s13555-022-00791-1. Epub 2022 Aug 19.

Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset.

Dermatol Ther (Heidelb). 2022 Jun;12(6):1337-1350. doi: 10.1007/s13555-022-00731-z. Epub 2022 May 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated.

作者信息

Sears A V, Woolf R T, Gribaleva E, Abdelrahman W, Robbie S, Menon B, Kirkham B, Smith C H, Pink A E

机构信息

St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation.

出版信息

Br J Dermatol. 2021 Apr;184(4):755-757. doi: 10.1111/bjd.19631. Epub 2021 Feb 28.

DOI:10.1111/bjd.19631

PMID:33107978

Abstract

摘要

相似文献

Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated.

Br J Dermatol. 2021 Apr;184(4):755-757. doi: 10.1111/bjd.19631. Epub 2021 Feb 28.

Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.

J Am Acad Dermatol. 2021 Jan;84(1):139-147. doi: 10.1016/j.jaad.2020.08.051. Epub 2020 Aug 18.

Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.

BMC Dermatol. 2020 Sep 22;20(1):8. doi: 10.1186/s12895-020-00103-0.

Real-world persistence with dupilumab among adults with atopic dermatitis.

Ann Allergy Asthma Immunol. 2021 Jan;126(1):40-45. doi: 10.1016/j.anai.2020.07.026. Epub 2020 Jul 31.

[Ocular symptoms associated with dupilumab in atopic dermatitis].

Ned Tijdschr Geneeskd. 2019 Mar 21;163:D3227.

Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.

Cornea. 2020 Jun;39(6):784-786. doi: 10.1097/ICO.0000000000002262.

Rosacea associated with dupilumab therapy.

J Dermatolog Treat. 2021 Feb;32(1):114-116. doi: 10.1080/09546634.2019.1624683. Epub 2019 Jun 9.

Type 2 Inflammation: Atopic Dermatitis, Asthma, and Hypereosinophilia Successfully Treated With Dupilumab.

J Investig Allergol Clin Immunol. 2021 Jun 22;31(3):261-263. doi: 10.18176/jiaci.0614. Epub 2020 Jul 30.

Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case report.

J Dtsch Dermatol Ges. 2020 Jul;18(7):740-742. doi: 10.1111/ddg.14074. Epub 2020 Mar 25.

Onset of Schamberg Disease and Resolution of Alopecia Areata During Treatment of Atopic Dermatitis With Dupilumab.

J Investig Allergol Clin Immunol. 2021 Feb 17;31(1):65-66. doi: 10.18176/jiaci.0541. Epub 2020 Jun 3.

引用本文的文献

Use of dupilumab for recalcitrant bullous pemphigoid: A case report.

SAGE Open Med Case Rep. 2024 Aug 22;12:2050313X241274855. doi: 10.1177/2050313X241274855. eCollection 2024.

Treatment patterns and factors associated with discontinuation of monoclonal antibodies.

SAGE Open Med. 2024 Aug 19;12:20503121241271817. doi: 10.1177/20503121241271817. eCollection 2024.

Immune-Targeted Therapies for Depression: Current Evidence for Antidepressant Effects of Monoclonal Antibodies.

J Clin Psychiatry. 2024 Jun 24;85(3):23nr15243. doi: 10.4088/JCP.23nr15243.

A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities.

JAAD Int. 2024 Jan 17;15:5-11. doi: 10.1016/j.jdin.2024.01.002. eCollection 2024 Jun.

Dupilumab-Associated Arthritis: A Dermatology-Rheumatology Perspective.

Am J Clin Dermatol. 2023 Nov;24(6):859-864. doi: 10.1007/s40257-023-00804-5. Epub 2023 Jun 22.

High loading-dose of dupilumab resulted in rapid disease control in pediatric patients with atopic dermatitis.

Front Immunol. 2023 Apr 20;14:1160710. doi: 10.3389/fimmu.2023.1160710. eCollection 2023.

Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management.

Cornea. 2023 Apr 1;42(4):507-519. doi: 10.1097/ICO.0000000000003162. Epub 2022 Dec 15.

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical Trials.

Dermatol Ther (Heidelb). 2022 Dec;12(12):2731-2746. doi: 10.1007/s13555-022-00822-x. Epub 2022 Oct 21.

Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study.

Dermatol Ther (Heidelb). 2022 Sep;12(9):2145-2160. doi: 10.1007/s13555-022-00791-1. Epub 2022 Aug 19.

Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset.

Dermatol Ther (Heidelb). 2022 Jun;12(6):1337-1350. doi: 10.1007/s13555-022-00731-z. Epub 2022 May 11.